Loading clinical trials...
Loading clinical trials...
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Conditions
Interventions
Durvalumab
Tremelimumab
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
July 14, 2017
Primary Completion Date
April 13, 2021
Completion Date
April 13, 2021
Last Updated
October 15, 2024
NCT04693377
NCT06705686
NCT04550494
NCT05691465
NCT06173362
NCT06305598
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions